Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-12-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于子公司西藏藏药（集团）利众院生物科技有限公司在四川省成立合资公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the establishment of a joint venture company by a subsidiary of the listed company. It details the investment amount, shareholding structure, business scope, and risk analysis. There is no financial data, earnings information, or detailed report content. The document is a formal announcement of a capital investment and joint venture formation, which fits the category of Capital/Financing Update (CAP). The document length is 3212 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2019-12-24 Chinese
关于控股子公司昆明贝克诺顿制药有限公司阿莫西林胶囊通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding its subsidiary's drug (Amoxicillin Capsules) passing a consistency evaluation by the National Medical Products Administration. It includes details about the drug, sales figures, regulatory approval, and risk warnings. The document is short (1193 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about product approval and related information that does not fit other specific categories.
2019-12-22 Chinese
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2017年限制性股票激励计划首次授予部分第二期解除限售的法律意见
Capital/Financing Update Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the second phase of lifting restrictions on shares granted under a 2017 restricted stock incentive plan of Kunming Pharmaceutical Group Co., Ltd. It details the approval, authorization, conditions met for lifting restrictions, and the number of shares and individuals involved. The document is a legal opinion related to a stock incentive plan and share restriction lifting, which is a capital/financing related matter rather than a financial report, management change, or voting result. It is not an announcement of a report publication but a substantive legal opinion document. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-12-12 Chinese
2017年限制性股票激励计划首次授予部分第二期解除限售暨上市公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding the unlocking and listing of restricted shares under a 2017 restricted stock incentive plan. It includes information about board and shareholder approvals, performance conditions, number of shares unlocked, and legal opinions. The content focuses on the lifting of restrictions on stock previously granted to management and key personnel, with no financial statements or earnings data presented. This is a corporate announcement about share unlocking and listing, not a financial report or earnings release. It fits best under the category of Transaction in Own Shares (POS), as it deals with the release and listing of restricted shares granted under an incentive plan.
2019-12-12 Chinese
独立董事关于九届十七次董事会会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's board meeting, specifically regarding the adjustment and revision of the company's convertible bond issuance plan and related reports. It contains independent opinions on legal compliance, feasibility, and impact on shareholders. The document is not a full financial report, earnings release, or regulatory filing but rather a formal opinion related to board decisions on financing matters. It is not a simple announcement or certification but a detailed independent opinion on board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board decisions and management matters.
2019-12-10 Chinese
关于公司公开发行可转换公司债券预案（修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's plan for a public issuance of convertible corporate bonds, including terms of the bonds, issuance scale, pricing, interest, conversion terms, redemption and repurchase clauses, and use of proceeds. It also includes extensive financial data such as balance sheets and profit statements for multiple years, indicating substantive financial information. The document is not merely an announcement of a report but contains detailed financial statements and management discussion relevant to the bond issuance. This fits the category of a Capital/Financing Update (CAP), as it provides comprehensive information about a financing activity (issuance of convertible bonds) and related financial data. The document length (15,000 characters) and content confirm it is not a brief announcement or a certification but a full financing update.
2019-12-10 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.